Systemic Chemotherapy with Combination of Immune Checkpoint Inhibitor and Tyrosine Kinase Inhibitor in Unresectable Hepatocellular Carcinoma

被引：0
|
作者：
Chon, Hye Yeon [1 ,2 ]
机构：
[1] Yonsei Univ, Coll Med, Dept Internal Med, Seoul, South Korea
[2] Yongin Severance Hosp, Dept Internal Med, 363 Dongbaekjukjeon Daero, Yongin 16995, South Korea
来源：
KOREAN JOURNAL OF GASTROENTEROLOGY | 2024年 / 83卷 / 02期
关键词：
ATEZOLIZUMAB;
D O I：
10.4166/kjg.2024.005
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：78 / 80
页数：3
相关论文
共 50 条
  • [31] Gut microbiota and metabolites associate with outcomes of immune checkpoint inhibitor-treated unresectable hepatocellular carcinoma
    Lee, Pei-Chang
    Wu, Chi-Jung
    Hung, Ya-Wen
    Lee, Chieh Ju
    Chi, Chen-Ta
    Lee, I-Cheng
    Yu-Lun, Kuo
    Chou, Shih-Hsuan
    Luo, Jiing-Chyuan
    Hou, Ming-Chih
    Huang, Yi-Hsiang
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (06)
  • [32] Clinical Efficacy and Safety of an Immune Checkpoint Inhibitor in Combination with Regorafenib Therapy as Second-Line Regimen for Patients with Unresectable Hepatocellular Carcinoma
    Li, Jinpeng
    Jia, Yuntao
    Shao, Changdong
    Li, Yuanming
    Song, Jinlong
    THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2023, 19 : 329 - 339
  • [33] A Systematic Review of Treatment-Related Adverse Events for Combination Therapy of Multiple Tyrosine Kinase Inhibitor and Immune Checkpoint Inhibitor
    Sawada, Takashi
    Narukawa, Mamoru
    CANCER CONTROL, 2024, 31
  • [34] Lessons From Immune Checkpoint Inhibitor Trials in Hepatocellular Carcinoma
    Mohr, Raphael
    Jost-Brinkmann, Fabian
    Ozdirik, Burcin
    Lambrecht, Joeri
    Hammerich, Linda
    Loosen, Sven H.
    Luedde, Tom
    Demir, Munevver
    Tacke, Frank
    Roderburg, Christoph
    FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [35] Current Landscape of Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma
    Ruff, Samantha M.
    Manne, Ashish
    Cloyd, Jordan M.
    Dillhoff, Mary
    Ejaz, Aslam
    Pawlik, Timothy M.
    CURRENT ONCOLOGY, 2023, 30 (06) : 5863 - 5875
  • [36] Current Landscape of Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma
    Machairas, Nikolaos
    Tsilimigras, Diamantis, I
    Pawlik, Timothy M.
    CANCERS, 2022, 14 (08)
  • [37] Hypercalcemia in a Patient with Cancer on an Immune Checkpoint Inhibitor, a Tyrosine Kinase Inhibitor, and Amiloride: Which Is the Culprit?
    Saldanha, Neves Horta Lima Carolina
    Sise, Meghan E.
    Gupta, Shruti
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2024, 35 (10):
  • [38] Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma
    Abd El Aziz, Mohamed A.
    Facciorusso, Antonio
    Nayfeh, Tarek
    Saadi, Samer
    Elnaggar, Mohamed
    Cotsoglou, Christian
    Sacco, Rodolfo
    VACCINES, 2020, 8 (04) : 1 - 19
  • [39] Tyrosine Kinase Inhibitor and Immune Checkpoint Inhibitor Responses in KIT-Mutant Metastatic Melanoma
    McKean, Meredith
    Oba, Junna
    Ma, Junsheng
    Roth, Katherine G.
    Wang, Wei-Lien
    Macedo, Mariana P.
    Carapeto, Fernando C. L.
    Haydu, Lauren E.
    Siroy, Alan E.
    Vo, Phuong
    Hong, David S.
    Eterovic, Agda K.
    Patel, Keyur Pravinchandra
    Bassett, Roland L., Jr.
    Grimm, Elizabeth A.
    Lazar, Alexander J.
    Woodman, Scott E.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2019, 139 (03) : 728 - 731
  • [40] Treatment response to durvalumab plus tremelimumab after progression with previous immune checkpoint inhibitor in unresectable hepatocellular carcinoma
    Mori, Nami
    Tamaki, Nobuharu
    Takaki, Shintaro
    Tsuji, Keiji
    Tada, Toshifumi
    Nakamura, Shinichiro
    Ochi, Hironori
    Mashiba, Toshie
    Doisaki, Masao
    Marusawa, Hiroyuki
    Kobashi, Haruhiko
    Fujii, Hideki
    Ogawa, Chikara
    Nonogi, Michiko
    Arai, Hirotaka
    Uchida, Yasushi
    Urawa, Naohito
    Narita, Ryoichi
    Akahane, Takehiro
    Kondo, Masahiko
    Yasui, Yutaka
    Tsuchiya, Kaoru
    Izumi, Namiki
    Kurosaki, Masayuki
    INVESTIGATIONAL NEW DRUGS, 2024, : 559 - 565
12345